Amani Therapeutics, Inc. — SEC Form D Filing
Amani Therapeutics, Inc. filed an SEC Form D on October 1, 2026, reporting $35.00M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 1, 2026
- Amount reported
- $35.00M
- Round stage
- Series A
- Industry
- Pharmaceuticals
- Website
- https://amanitx.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients with treatment-resistant schizophrenia and schizoaffective disorder lack access to an effective treatment, clozapine, because its use is limited by severe safety concerns, specifically neutropenia, and burdensome blood-monitoring requirements.
Solution
Amani Therapeutics is developing AM-01, a fixed-dose combination product of clozapine and a Phase 3-ready NCE, to provide clozapine's efficacy while mitigating its safety liabilities like severe neutropenia and reducing monitoring requirements.
Verdict
This cleared because investors underwrote the de-risking of an established efficacy profile by addressing a known toxicity, not because the company was proving out a novel therapeutic mechanism. The implicit bet was on regulatory pathway efficiency and market share capture from a currently underutilized drug, assuming the safety improvements would translate directly into broader clinical adoption. Upside was limited by the reliance on incremental improvement to an existing molecule rather than the creation of entirely new therapeutic optionality.
Source: SEC EDGAR Form D filing